INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disorder of the joints that, if left untreated, leads to joint damage and disability. Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) are recommended as first-line therapy for patients with RA, with the goal of achieving remission or low disease activity [1, 2] . However, a proportion of patients fail to achieve this goal with csDMARDs alone, and the addition of or switch to a biologic DMARD, such as tocilizumab (TCZ), may provide increased efficacy [1, 2] .
Tocilizumab is the first approved drug for RA that inhibits the interleukin 6 (IL-6) receptor alpha. TCZ is approved for the treatment of patients with moderate to severe active RA who have had an inadequate response to one or more DMARDs [3] . TCZ has been approved to be used in combination with csDMARDs or as monotherapy, making it an attractive therapy for patients who cannot tolerate csDMARDs [4] [5] [6] [7] . In addition, intravenous TCZ can be administered in 2 different doses (4 and 8 mg/ kg) and adjusted to the individual patient's disease activity.
The recommended dosing regimen of intravenous TCZ varies around the world. In European countries and Japan, the recommended starting dose of TCZ is 8 mg/kg every 4 weeks. In the United States (US), the recommended starting dose of intravenous TCZ for patients with moderate to severe RA, either as in combination with csDMARDs or as a monotherapy, is 4 mg/kg every 4 weeks. The dose may be increased to 8 mg/kg based on clinical response, at the physician's discretion [3] . Data from clinical trials have shown significant efficacy with both the 4-and 8-mg/ kg doses of TCZ in patients with RA [8] [9] [10] [11] [12] [13] . Overall, patients were more likely to achieve better disease activity responses with TCZ 8 mg/ kg than with TCZ 4 mg/kg, but individual responses varied [8] [9] [10] [11] [12] [13] . In real-world settings in the US, the option to change the dose of TCZ based on clinical response allows physicians to tailor the treatment dose to the disease activity; however, data on dose escalation in everyday practice are limited. This descriptive analysis provides data on dosing patterns in the US, where there is higher variability in TCZ dosing than in other countries. The objective of this analysis was to describe the patterns of intravenous TCZ dose escalation in a real-world clinical setting over 6 months of therapy using data from a large, observational US patient registry (Corrona). Descriptive data showing changes in clinical disease activity, functional status, and inflammatory markers at 3 and 6 months after therapy with different dose escalation patterns of TCZ were also provided. Clinical data were collected in CERTAIN for patients at baseline and at 3, 6, 9, and 12 months; however, for this analysis, data were restricted to those collected at 3 and 6 months due to the low number of patients who had data beyond 6 months. These assessments included Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP), 
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RESULTS
TCZ Dosing Patterns
As of August 29, 2013, there were a total of 213 patients eligible for inclusion in this analysis;
199 patients (93.4%) initiated TCZ at 4 mg/kg and 14 patients (6.6%) initiated TCZ at 8 mg/kg ( Fig. 1) . Among the 199 patients who initiated TCZ at 4 mg/kg, 86 (40.3% of the total population) were escalated to TCZ 8 mg/kg after the 3-month visit and by the 6-month follow-up visit (Group 1), and 110 (51.6% of the total population) were escalated to TCZ 8 mg/kg by or at 3 months and remained on this dose during the observation period (Group 2). The remaining patients (Group 3) consisted of three individuals whose TCZ dose was escalated from 4 to 8 mg/kg at 3 months before it was returned to 4 mg/kg at 6 months, and an additional 14 who initiated TCZ at 8 mg/kg and were thus unable to have their treatment escalated ( Fig. 1 ). These patients were excluded from further analysis due to the small sample size.
Within Group 1, 45 patients remained on their initial TCZ dose of 4 mg/kg through 6 months and 41 patients had their TCZ dose escalated to 8 mg/kg by 6 months (i.e., any time after the 3-month visit and prior to the 6-month visit). Within Group 2, 82 patients had their dose escalated prior to the 3-month visit and 28 patients had their dose escalated at the time of the 3-month visit.
Baseline Characteristics
The majority of the 213 patients eligible for analysis were female and white, with a median age of 56.5 years (Table 1) .7) years and 11.6 (8.9) years for Groups 1 and 2, respectively] and high mean baseline disease activity (Table 2) , and the majority had a history of multiple biologic DMARD treatment failures prior to initiation of TCZ (Table 3) . (Fig. 2a) . In addition, patients in Group 1 exhibited decreases in all disease activity measures (CDAI, DAS28-CRP, pain, fatigue, and CRP) at 3 and 6 months from baseline ( Of the patients who escalated to TCZ 8 mg/kg by or at 3 months (Group 2), at 3 and 6 months, respectively, 55% and 67% had achieved an MCID based on CDAI, 50% and 67% had achieved DAS28-CRP low disease activity or remission, and 59% and 66% had achieved a moderate or good EULAR response (Fig. 3a) . Similar to patients in Group 1, patients in 
DISCUSSION
This study, among the first to describe how TCZ dose is being escalated in real-world settings in the US, found that most patients have their dose escalated within 6 months of initiation. remaining at TCZ 4 mg/kg; however, both groups of patients (those who escalated by or at 3 months and those who did not) exhibited significant improvements in disease activity levels at both 3 and 6 months. These data suggest that in real-world settings, physicians respond to disease activity levels and that the option to adjust TCZ dose based on individual clinical responses may have provided an additional benefit to the patients.
In this study, only 22.6% of patients remained at the TCZ 4-mg/kg dose 6 months after initiation of therapy and 1.5% returned to 4 mg/kg after an initial increase to 8 mg/kg. While it is likely that dose reductions in these patients were due to safety concerns, previous studies have shown that a sufficient response with TCZ 8 mg/kg may warrant dose reduction.
In a retrospective study of 22 patients with RA who received TCZ 8 mg/kg for 6 months and had their dose tapered to 4 mg/kg because of low disease activity, 55% of patients remained in disease remission 6 months after the dose 
